Secondary analysis of the phase 3 PROpel trial in first-line metastatic castration-resistant prostate cancer: olaparib plus abiraterone vs placebo plus abiraterone numerically favoured rPFS in BRCA2 (HR 0.20), ATM (HR 0.55) and CDK12 (HR 0.51) mutation subgroups.
Secondary analysis
Shore et al. Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel